
999986 | 4ME 16:0 Diether DG
1,2-di-O-phytanyl-sn-glycerol

4ME 16:0 Diether DG
1,2-di-O-phytanyl-sn-glycerol
In biochemical signaling, diacylglycerol (DAG) functions as a second messenger signaling lipid, and is a product of the hydrolysis of the phospholipid PIP2 (phosphatidylinositolbisphosphate) by the enzyme phospholipase C (PLC) (a membrane-bound enzyme) that, through the same reaction, produces inositol trisphosphate (IP3). Although inositol trisphosphate (IP3) diffuses into the cytosol, DAG remains within the plasma membrane due to its hydrophobic properties. IP3 stimulates the release of calcium ions from the smooth endoplasmic reticulum, whereas DAG is a physiological activator of protein kinase C (PKC). The production of DAG in the membrane facilitates translocation of PKC from the cytosol to the plasma membrane. (See References) Diacylglycerol mimicks the effects of the tumor-promoting compounds phorbol esters.
Storage:Diacylglycerols are conveniently stored in chloroform solutions in glass vials with teflon-lined caps at -20°C. Under these conditions acyl migration is minimal. Avoid plastic when handling chloroform solutions.
Delivery to cells:Dry samples of diacylglycerol in chloroform, using a stream of nitrogen. Dissolve the residue in an appropriate volume of ethanol or DMSO, then dilute to the desired aqueous medium.
Effective concentration:Most biological responses saturate at 20 to 250 µM sn-1,2-dioctanoylglycerol. Only sn-1,2 isomers appear to be active.
- ChemDraw File
- 3D Structure
- Structure
- Safety Data Sheet
- Safety Data Sheet
Iaea DB, Spahr ZR, Singh RK, Chan RB, Zhou B, Bareja R, Elemento O, Di Paolo G, Zhang X, Maxfield FR. Stable reduction of STARD4 alters cholesterol regulation and lipid homeostasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Apr;1865(4):158609. doi: 10.1016/j.bbalip.2020.158609. Epub 2020 Jan 7. PMID: 31917335; PMCID: PMC6996790.
PubMed ID: 31917335Meyer S, Thiel V, Joergensen RG, Sundrum A. Relationships between feeding and microbial faeces indices in dairy cows at different milk yield levels. PLoS One. 2019 Aug 20;14(8):e0221266. doi: 10.1371/journal.pone.0221266. eCollection 2019.
PubMed ID: 31430322Lorem ipsum dolor sit amet, omnis melius gloriatur at his, veri exerci conclusionemque pro eu, simul possit ancillae an vix. Ut case iudico pro, vero necessitatibus te quo, ea sit regione appetere. Exerci persequeris pro in, usu brute iudico erroribus at. Quem posse nostro eam ei, at tale iriure admodum sed.
- Certificate of Analysis(Lot No. 999986C-50MG-A-013and 6396OKA013)
- Certificate of Analysis(Lot No. 999986C-5MG-A-013and 6396CHA013)
- Certificate of Analysis(Lot No. 999986O-50MG-A-013and 6396OKA013)
- Certificate of Analysis(Lot No. 999986O-5MG-A-013and 6396OHA013)
- Certificate of Analysis(Lot No. 999986C-200MG-A-013and 6396CNA013)
- Certificate of Analysis(Lot No. 999986O-200MG-A-013and 6396ONA013)
- Certificate of Analysis(Lot No. 999986O-200MG-B-013and 6396ONB013)
- Certificate of Analysis(Lot No. 999986C-5MG-B-013and 6396CHB013)
- Certificate of Analysis(Lot No. 999986O-5MG-A-014and 6396OHA014)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括:(1)ResearchProductsHighestPurityLipidReagents(2)cGMPManufacturingAPI&ContractManufacturing(3)AdjuvantsImmunotherapy&VaccineDevelopment(4)AnalyticalServicesLipidAnalysis(5)LipidomicsMassSpecStandards,Antibodies&LipidToolbox(6)Formulationsliposomes&Nanoparticles(7)EquipmentLiposomeProductionTools(8)CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇,磷脂酰肌醇-4,5-二磷酸,磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂,磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo(4-氧-4-羟-四甲基呱啶氮氧自由基)标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly(Ethyleneglycol)-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
为了帮助临床医师客观地了解NSAIDs,避开制药公司的导向以便更好地指导临床实践,本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸(阿司匹林)应用至临床到现在,已经超过100个年头。1948年第一个非水杨酸类的NSAIDs保泰松问世后,抗炎镇痛药的种类迅速增加,如吲哚美辛、双氯芬酸、布洛芬、萘普生等,使NSAIDs“家族”迅速壮大。作为其“元老”的保泰松,虽然具有很强的抗炎镇痛作用,但潜在的严重副作用(再生障碍性贫血等)使其被淘汰。
1971年,环氧化酶(COX)理论解释了NSAIDs的作用机制。NSAIDs通过抑制COX,阻止花生四烯酸转变为前列腺素,后者既是炎症介质,又有生理功能。因此NSAIDs在抗炎镇痛的同时可引起胃肠道反应。20年后,研究者发现,COX存在不同的异构体,从而提出了COX异构体理论。认为COX存在两个异构体,一个是构建型的,称COX-1,以维持生理平衡为主;另一个是诱导型的称COX-2,主要参与炎症性前列腺素合成。
1994年,氟舒胺成为第一个被报道在实验室证实具有选择性COX-2抑制作用的NSAIDs,但在1996年III期临床试验总结时发现,该药具有肝毒性而未能获准上市。1995年Lancet上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性COX-2抑制剂”,虽然同年该期刊刊出几篇读者来信,对此提法提出争议,但是后来人们仍普遍接受这种提法。1999年,针对COX异构体理论研制的昔布类药物(塞来昔布和罗非昔布)上市,被称为“特异性COX-2抑制剂”。
虽然COX异构体理论尚需完善,但它的确是新型NSAIDs研制的一个突破口。除已经问世的昔布类药物外,新的昔布类Etoricoxib、parecoxib、valdecoxib也将投入临床。新研制的COX-2抑制剂不只限于昔布类,磺酰苯胺类也是研制新型COX-2抑制剂的方向,如氟舒胺、NS-398、HN-56249等。另外,针对COX和脂氧化酶(5-lipoxygenase

